Every 68 seconds someone in America develops Alzheimer’s disease – a devastating and irreversible brain disease that slowly destroys an individual’s cognitive functioning, including memory and thought.
Alzheimer’s currently affects more than 5.2 million people in the United States and more than 35.6 million worldwide. As the population ages, the number of people diagnosed with Alzheimer’s after age 65 will double every five years, while the number of individuals 85 years and older with this disease will triple by 2050.
These statistics provide a much-needed Alzheimer’s reality check; this terrible disease is the sixth leading cause of death in the United States and there is currently no diagnostic test, no treatment and no cure.
The U.S. Senate recently held a hearing in the Senate Appropriations Committee on the devastating impacts of Alzheimer’s – both personal and economic – and the state of current research initiatives. I invited my former colleague, Congressman Dennis Moore of Lenexa to share his personal testimony at the hearing.
Rep. Moore was diagnosed with Alzheimer’s in June 2011, after serving Kansas’ Third District from 1999 to 2011.
“An epidemic is upon us and too many families are in situations like mine facing a fatal disease that currently has no way to prevent, cure or even slow its progression,” Rep. Moore told the Committee.
I asked my former colleague what health care professionals are telling him he can do about his diagnosis. Dennis responded, “Basically to take the medication that they diagnosed for me… and also to get some exercise, which I try to do on a daily basis. My wife very much encourages me to do that. I’m a smart husband, I say, yes dear.”
I truly appreciate Congressman Moore’s willingness to testify before the Senate on behalf of the thousands of Americans and people around the world who have encountered Alzheimer’s disease. The way he is living his life gives others courage and hope, and I commend him and his wife Stephene for their continued public service.
As a nation, it is critical that we confront the pending Alzheimer’s health care crisis and its financial costs as the baby boomer generation ages. Caring for those with Alzheimer’s and other dementias is expected to cost $203 billion this year, with $142 billion covered by the federal government through Medicare and Medicaid. A study by the RAND Corporation stated that the cost of dementia care is projected to double over the next 30 years, surpassing health care expenses for both heart disease and cancer. Yet, for every $270 Medicare and Medicaid spends caring for individuals with Alzheimer’s, the federal government currently spends only $1 on Alzheimer’s research.
Alzheimer’s has become a disease to define a generation, but if we focus and prioritize our research capacity, it does not need to continue as an inevitable part of aging. Research suggests that more progress could be made with a boost in investment. One study found that a breakthrough against Alzheimer’s that delays the onset of the disease by five years would mean an annual savings of $447 billion by 2050.
A sustained federal commitment to research for Alzheimer’s will lower costs and improve health outcomes for people living with the disease today and into the future. As Ranking Member of the Senate Appropriations Subcommittee that funds the National Institute of Health (NIH), I am committed to prioritizing funding for Alzheimer’s research.
Last year, the omnibus appropriations bill increased funding for the NIH to support Alzheimer’s research, and supported the initial year of funding for the new initiative to map the human brain. Both projects will increase our understanding of the underlying causes of Alzheimer’s, unlock the mysteries of the makeup and functioning of the brain, and bring us closer to effective treatments and one day – hopefully – a cure.
It is time to truly pledge to defeat Alzheimer’s disease in the next decade. The health and financial future of our nation are at stake and the United States cannot afford to ignore such a threat. Together, we can make a sustained commitment to Alzheimer’s research that will benefit our nation and bring hope to future generations of Americans. The challenge is ours and the moment to act is now.